Background: To date, the stability of human epidermal growth factor receptor 2 (HER2)-positive primary breast carcinomas during disease progression and the role of intervening trastuzumab treatment in the loss of HER2-positive status in paired metastases remain under-investigated.
introduction
Trastuzumab combined with chemotherapy is the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast carcinoma. Previous studies have shown that patients with HER2-positive metastatic breast carcinoma who receive trastuzumab have a better prognosis than those with HER2-negative metastatic breast carcinoma or those with HER2-positive metastatic breast carcinoma who do not receive trastuzumab treatment [1] [2] [3] [4] . Thus, accurate determination of HER2 status in metastatic breast carcinoma is important to maximize the benefit and minimize the unnecessary toxicity of trastuzumab. However, HER2 and hormone receptor status are usually assessed in newly diagnosed primary breast carcinoma, and the test results are frequently used to guide therapy in the metastatic setting, even if metastasis occurs many years after the initial HER2 testing. This is largely because of the assumption that HER2 expression is quite stable during disease progression and the status in the primary carcinoma is representative of that in metastatic carcinoma. Also, the difficulty of sampling metastatic tumor and limited availability of metastatic tumor tissue for HER2 testing are implicated factors. Because breast cancer is generally a chronic disease and because most patients have already received various chemotherapy regimens and/or targeted therapies by the time of relapse, controversy still exists as to how stable HER2 status actually is during disease progression or following intervening systemic therapy.
Our group, as well as others, previously demonstrated that HER2 status (both positive and negative status) is generally stable during disease progression [5] [6] [7] [8] [9] and that when HER2 status does change, loss of HER2 protein overexpression and/or gene amplification seems more frequent than gain [6, [9] [10] [11] [12] . It is unknown whether loss of HER2-positive status is due to treatment with trastuzumab, a humanized anti-HER2 monoclonal antibody. To date, published studies focusing on the stability of HER2-positive status during disease progression are sparse, probably because of the low frequency of HER2-positive breast carcinomas (i.e. they account for only 15% of all invasive breast carcinomas) and the difficulty of obtaining or testing paired metastatic tumors.
Few studies have evaluated the effect of trastuzumab on HER2 status. In a preclinical study, Ropero et al. [13] reported that trastuzumab down-regulated HER2 protein level by 27%. Some studies have shown that the serum level of HER2 extracellular domain decreased following trastuzumab therapy [11, [14] [15] [16] [17] . Other studies compared HER2 status between newly diagnosed breast carcinomas and surgically resected tumors following trastuzumab-based neoadjuvant therapy and reported a positive-to-negative conversion in HER2 status in 12%-43% of the patients [17] [18] [19] [20] . However, the role of intervening trastuzumab treatment in the loss of HER2-positive status in metastatic tumors is under-investigated and is mostly reported in case reports or small series. For example, Pectasides et al. [11] studied 11 patients with HER2-positive primary breast carcinomas and paired post-trastuzumab metastatic tumors and found a positive-to-negative conversion of HER2 status in two (18.2%) patients. Kunitomo et al. [21] reported a single case of metastatic carcinoma with an outgrowth of HER2-negative tumor cells following trastuzumab treatment of a HER2-positive primary tumor. Similarly, Dawood et al. [22] described a patient with HER2-positive stage I breast cancer who, after receiving adjuvant trastuzumab, developed a HER2-negative metastatic tumor in a mediastinal lymph node. While these findings suggest that trastuzumab treatment may down-regulate HER2 expression, none of these studies included a control group in which patients with HER2-positive primary breast carcinomas were trastuzumab naive before their metastatic tumors were sampled. It is thus uncertain whether the HER2 status change was caused by the trastuzumab treatment or by other confounding factors.
It is well known that the level of HER2 overexpression and/or gene amplification is inversely correlated with the expression level of hormone receptors [23] . A relatively low expression level of hormone receptors is often seen in patients with HER2-positive tumors, and this may partly explain the relative resistance of HER2-positive tumors to endocrine therapy even though these tumors show positive hormone receptor status. Although a study suggested that trastuzumab treatment may up-regulate estrogen receptor (ER) expression in HER2-positive tumors, thereby increasing their sensitivity to antiestrogen therapy [24] , it included only a few patients and lacked a control group.
In this retrospective study, we examined the stability of HER2-positive status during disease progression and the impact of trastuzumab treatment on the loss of HER2-positive status by comparing HER2 status between primary and paired metastatic tumors in patients with and without intervening trastuzumab treatment. We also evaluated whether ER status might change in these patients.
materials and methods

patients and samples
This study included patients with HER2-positive primary invasive breast carcinoma who subsequently developed metastatic carcinoma and who had HER2 and ER status available for both the newly diagnosed primary breast carcinoma and the paired metastatic carcinoma. Briefly, we first identified metastatic breast carcinomas that were sampled at The University of Texas MD Anderson Cancer Center from January 2000 to October 2009 with known HER2 and ER status. We then searched our institutional patient care database for the paired primary breast carcinomas and recorded their HER2, ER status, and clinicopathologic characteristics. We identified a total of 66 patients. Each patient had one metastatic carcinoma for which both receptor status were available, although eight patients had more than one metastatic tumor. The time interval between primary and metastatic carcinoma was calculated from the initial diagnosis of the primary breast carcinoma to the sampling of the metastatic carcinoma; it was >12 months in most patients. For intervening treatment, 38 of the 66 patients received trastuzumab and 28 did not (control group) before the metastatic tumors were sampled. In the trastuzumab-treated patients, trastuzumab was administered concomitantly or sequentially with polychemotherapy, mostly in the adjuvant setting. The median duration of trastuzumab treatment was 12 months (range 3-66 months; mean 18 months); the treatment in some patients was intermittent or prolonged. Sixty of the 66 patients had received chemotherapy (anthracycline-based regimens with or without a taxane). In the remaining six patients, the metastasis was discovered before chemotherapy was initiated. Thirty patients had ER-positive primary carcinoma, 29 of whom had been treated with endocrine therapy before metastatic tumors were sampled. Of these 29 patients, 22 received tamoxifen, alone or with aromatase inhibitor. The characteristics of the 66 patients and their primary and paired metastatic tumors are summarized in Tables 1 and 2 .
For all the newly diagnosed primary carcinomas, tumor tissues were sampled via core needle biopsy or surgical resection and HER2 and ER status were tested either at MD Anderson or at an outside referral hospital from December 1986 to May 2009. If the biomarkers of a primary breast carcinoma were tested at an outside hospital, the outside pathology report and the pathology slides were reviewed and confirmed by pathologists at MD Anderson whenever possible, and biomarkers were retested in some patients before starting treatment at our institution.
For all the metastatic carcinomas, tumor tissues were sampled via fineneedle aspiration and HER2 and ER status were tested at MD Anderson from January 2000 to October 2009.
HER2 and ER testing and scoring
In the primary breast carcinomas, HER2 status was determined on tissue sections using immunohistochemistry (IHC) (n = 25), FISH (n = 10), or both (n = 31). In the metastatic tumors, HER2 status was determined using FISH with or without prior IHC (n = 64) or IHC only on cell block paraffin sections (n = 2). Membranous staining in the IHC assay was scored (0, 1+, 2+, 3+) according to the manufacturer's specifications (Dako, Carpinteria, CA).
HER2 status was defined as positive if an IHC assay demonstrated 3+ staining and/or FISH demonstrated a gene copy ratio of HER2:CEP17 ‡2.0. An IHC score of 0 or 1+ was considered negative. Patients with a tumor with an IHC score of 2+ but without confirmatory FISH results were excluded from the study. We used the conventional/manufacturer's scoring criterion to interpret the FISH results to ensure that the same scoring criterion was original article Annals of Oncology used for each tumor pairs because 57 (86%) of the primary tumors and 33 (50%) of the metastatic tumors in this study were tested and scored before the new American Society of Clinical Oncology/College of American Pathologists guidelines for HER2 testing were published in 2007 [25] .
The ER status of primary tumors was tested on histologic sections using IHC and the ER status of metastatic tumors was determined on cytologic smear or cell block tissue using an immunocytochemical method that we previously validated [26] . ER status was defined as positive if ‡10% of tumor cells demonstrated nuclear staining. This cut-off value was used because the ER status of most primary tumors in this study was determined using this cut-off value.
statistical analysis
We compared the HER2 and ER status of the metastatic tumors with that of the paired primary tumors. The agreement of their status between primary and metastatic tumors was expressed using both concordance and Cohen's kappa coefficients, with a corresponding 95% confidence interval. The relationship between kappa values and level of agreement was proposed by Landis and Koch [27] : slight agreement, 0.0020.20; fair agreement, 0.212 0.40; moderate agreement, 0.4120.60; substantial agreement, 0.6120.80; and almost perfect agreement, 0.8121.00. We compared the change in receptor status between the paired groups for each factor using Fisher's exact test or chi-square test. P <0.05 was considered significant.
This study was conducted with the approval of the MD Anderson's Institutional Review Board, which waived the requirement for informed consent.
results
For the trastuzumab-treated group and the control group, the mean age at the time of diagnosis of primary breast carcinoma was 49 years (range 26-74 years) and 51 years (range 30-79 years), respectively. The mean time elapsed between diagnosis of primary breast carcinoma and sampling of the paired metastatic tumor was 55 months (range 3-196 months) for the trastuzumab-treated group and 35 months (range 1-144 months) for the control group. In the trastuzumab-treated group, 19 (50%) patients had locoregional metastases and 19 (50%) had distant metastases; in the control group, 13 (46%) patients had locoregional metastases and 15 (54%) patients had distant metastases ( Table 2) .
The overall agreement rate in HER2 status between primary and paired metastatic tumors was 84.9% (56/66); the rate of agreement was 86.8% (33/38) in the trastuzumab-treated group and 82.1% (23/28) in the control group. The difference in the agreement rate between the two groups was not statistically significant (P = 0.858).
Rates of conversion from HER2-positive to HER2-negative status were not significantly related to chemotherapy (received versus not received), endocrine therapy (received versus not received), metastasis site (locoregional versus distant), or time to relapse (<5 versus ‡5 years). This held true in both trastuzumab-treated and control groups (Table 3) .
Of the 10 (15.1%) patients (5 in each group) who underwent a positive-to-negative conversion in HER2 status (Table 4) , 3 (patients 1, 3, and 4 in Table 4 ) underwent HER2 testing of the primary breast carcinoma at an outside hospital but did not have the testing slides available for review by MD Anderson pathologists. One patient (5) had a primary breast carcinoma that was reported as IHC 3+ at an outside hospital but was FISHnegative when retested at MD Anderson. One patient (2) had two primary breast carcinoma nodules identified simultaneously. Although both nodules had a score of 2+ by IHC, one nodule was HER2 positive (low gene amplification) and the other nodule was HER2 negative as determined by FISH. One patient (7) had a primary breast carcinoma that had a 2+ score by IHC but a low HER2 gene amplification by FISH (Table 4) . The overall ER concordance rate between primary and paired metastatic tumors was 78.8% (52/66); the rate was 79.0% (30/38) in the trastuzumab-treated group and 78.6% (22/28) in the control group (Table 5) . A conversion from ER-negative to ER-positive status was found in 19.0% (4/21) of the patients in trastuzumab-treated group and in 13.3% (2/15) of those in the control group. There was no statistically significant difference in ER status change between the trastuzumab-treated and control groups (P = 0.990).
Of the 14 (21.2%) patients with discordant ER status, 8 underwent a positive-to-negative conversion and 6 underwent a negative-to-positive conversion. In seven patients, the ER score was marginally positive (i.e. 10%) in one site (primary tumor or metastasis) and either positive or negative in the other. In the remaining seven patients, the ER status of the primary breast tumor was determined at an outside hospital, and only two of these patients had testing slides available for review by MD Anderson pathologists. . Of note, positive-to-negative conversion of HER2 status occurred slightly more frequently in the control group (17.9%) than in the trastuzumab-treated group (13.2%), suggesting that the loss of HER2-positive status was not due to trastuzumab treatment. We further observed that there was no significant difference in HER2 status change between patients who received chemotherapy and those who did not, between patients who received endocrine therapy and those who did not, between patients with locoregional and those with distant metastases, and between patients with time to relapse <5 or ‡5 years. It has been speculated that cells that metastasize locally via lymphatics may be biologically distinct from cells that have the capacity to invade blood vessels and therefore to metastasize to distant sites. Distant metastases are often identified years after the initial diagnosis of primary cancers. Some studies have shown that discordance in HER2 status occurs more frequently in distant metastases than in locoregional metastases [28, 29] . For instance, in their study, Santinelli et al. [29] observed discordance in HER-2 status in 6.7% of synchronous lymph node metastases, 13.3% of local recurrences, and 28.6% of metachronous distant metastases, compared with the primary breast carcinomas. In the present study, however, the rate of HER2 status agreement between the primary breast carcinomas and the locoregional metastases was similar to the rate of HER2 status agreement between the primary carcinomas and the distant metastases, and the time to relapse (i.e. <5 or ‡5 years) did not significantly affect HER2 status (Table 3) .
Clonal selection, with subsequent clonal expansion during tumor progression, has been proposed as the mechanism underlying the differences in the genetic composition of primary and metastatic breast carcinomas. Previous studies have suggested that the primary tumor may contain a very small percentage of cells (i.e. clones) that are responsible for metastasis. These clones may not be detectable in the primary tumor and may have genetic features different from the majority of cells in the primary tumor [30, 31] . The possible selection pressures of the growth environment include the immune surveillance of the host, stromal or growth factor interactions, nutritional deficiencies, hypoxia, and targeted therapy [32] . Clonal selection likely increases the adaptability of the tumor to these different environmental challenges. Treatment-induced selection was presumed by Kunitomo et al. [21] in their report demonstrating an outgrowth of HER2-negative cells in metastatic site following the obliteration of HER2-positive tumor cells by trastuzumab. However, based on our findings, we could not confirm the presence of trastuzumab-induced selection.
In this study, we observed an overall good agreement rate in HER2 status between the primary and paired metastatic breast carcinomas despite the discordance in HER2 status observed in 10 patients. After evaluating the details of HER2 result in these patients, it seems that variability in sampling, testing, and interpretation may play some role in the discordance. For instance, most primary carcinomas were collected and tested at an outside hospital, and all metastatic carcinomas were sampled and tested at MD Anderson, which reflects the common practice in a tertiary cancer center. Furthermore, in patient 5 in Table 4 , it is difficult to determine in this patient which of the two results (IHC and FISH) represents the true HER2 status of the primary carcinoma. According to the 2007 American Society of Clinical Oncology/College of American Pathologists guidelines for HER2 testing [25] , IHC and FISH are equally reliable and there is no relative superiority of one test over the others if properly carried out. However, our group, as well as others, has occasionally encountered tumors that were HER2 positive by IHC (3+) but HER2 negative by FISH [33] [34] [35] . For another patient (2), one could argue that the discordance would not exist if the HER2-negative metastatic carcinoma were derived from the HER2-negative primary carcinoma nodule. In addition, the difficulty in interpreting the 2+ IHC result or the FISH result showing low amplification may be implicated in the HER2 discordance observed in patient 2 as well as in patient 7. It is conceivable that the agreement rate in HER2 status would have been higher if sampling, testing methods, and interpretation were more uniform. On the other hand, if patients with uncertain HER2 status in the primary tumor (i.e. patients 1, 2, 3, 4, 5, and 7) were excluded from this study, we would get a higher overall concordance rate of 93.3% (56/60). Since the first five patients were trastuzumab treated and the patient 7 was trastuzumab naive, the corresponding agreement rate for the trastuzumabtreated group would be 100% (33/33), whereas the rate for the control group would be 85.2% (23/27) , also supporting the notion that loss of HER2-positive status may not be trastuzumab related.
The present study is superior to previously published studies in that it included a trastuzumab-naive control group to examine whether loss of HER2-positive status was due to trastuzumab-based therapy. The control group and trastuzumab group appear to be relatively balanced for age, race, histologic type, nuclear grade, tumor size, and hormone receptor status. Although this series is still quite small, it is relatively larger than published studies that evaluated stability of HER2-positive status in breast carcinomas [11, 21, 22] . This is partly because of the wide use of fine-needle aspiration technique to sample metastatic tumors in our institution and the well-validated methodology for testing biomarker status in fine-needle aspiration specimens in our laboratory [6, 26, 33] . Certainly, larger studies are still needed to confirm these findings.
Our study did have limitations. First, the patients received various systemic therapy regimens for various durations. However, this problem is intrinsic to any retrospective study comparing between primary and metastatic tumors since metastasis might be discovered before the completion of required systemic therapy. Second, it would have been preferable to test and score the biomarkers of both primary and metastatic tumors at MD Anderson, especially for those pairs showing discordant HER2 status. However, we were unable to obtain the pathology samples of the primary tumors for some patients, especially those diagnosed before 2002. It has been shown, in a preclinical study, that anti-HER2 treatment with trastuzumab up-regulated ER levels and restored the sensitivity to endocrine therapy [36] . Moreover, several studies have reported a conversion of ER-negative-topositive status following trastuzumab therapy [18, 20, 24] . Mittendorf et al. [20] found a conversion from ER-negative phenotype to ER-positive phenotype following preoperative trastuzumab treatment in 4 of the 20 patients studied. In a study of 10 patients, Munzone et al. [24] found a similar negative-to-positive conversion in ER status in three patients following trastuzumab-based therapy. In another study, Harris et al. [18] observed such ER status conversion in only one of 27 patients after preoperative exposure to trastuzumab and vinorelbine. When we compared primary and metastatic tumors, we found that a negative-to-positive conversion of ER status occurred in both the trastuzumab-treated group and the control group. Although this type of conversion occurred more frequently in the trastuzumab-treated patients (19.0% versus 13.3%), the difference was not statistically significant. In addition, we observed a positive-to-negative conversion of ER status in both groups. Collectively, these findings suggest that ER status change is unlikely due to trastuzumab-based therapy. As in the cases with HER2 status discordance, variation in sampling, testing, and interpretation between primary and metastatic tumors may be implicated in ER discordance. In particular, 7 of the 14 patients with ER discordance had borderline ER scores, which are often associated with interobserver variation and misinterpretation.
In summary, we found that positive-to-negative conversion of HER2 status does occur occasionally during disease progression. The underlying mechanism of this conversion remains to be elucidated. Based on our findings, however, trastuzumab treatment does not seem responsible for the loss of HER2-positive status in metastatic breast carcinomas. We also found no evidence that ER status change was related to trastuzumab treatment. Because of the limitations of this study, the findings should be validated by larger well-controlled studies. 
